Lantern Pharma Uses AI to Slash Cancer Drug Timelines | LP-184 Trial Success & Starlight Spinoff

For biotech investors, healthcare innovators, and AI technology enthusiasts — this New to The Street interview from the New York Stock Exchange features Lantern Pharma’s CEO, detailing how the company’s proprietary RADR® AI platform is transforming cancer drug discovery — delivering clinical-ready therapies in months instead of years.

Lantern has already advanced three oncology drugs into clinical trials within two years and now operates 12+ active cancer development programs. Patients are being dosed today across multiple indications.
The company’s lead therapy, LP-184, a synthetically lethal small molecule developed entirely using AI, delivered positive clinical results across a 63-patient trial. The study reached all major safety and dosing endpoints, demonstrated patient responses predicted by AI models, and produced a greater than 50{d450b60efc35a2e17361b5d57bc194208ff1ac62c46bd45a026f4271e6a4dcc4} clinical benefit rate at effective doses — leading directly to three new trial launches.

Lantern’s breakthrough RADR® AI platform now functions at the scale of what once required thousands of researchers — analyzing targets, optimizing drug candidates, and identifying patient responders in a single workflow. Lantern is expanding global platform access for partnerships, monetizing its technology through IP licensing, co-development agreements, and equity participation.

A major growth catalyst is the spin-off of Starlight Therapeutics, a new CNS-focused oncology company born from AI discovery identifying brain cancer potential for Lantern compounds. Starlight has secured FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, with drugs already manufactured and entering Phase I/II trials targeting glioblastoma and pediatric brain cancers. Lantern shareholders will receive ownership in the spinoff entity.

Lantern believes its platform can reshape the economics of drug development — especially for underserved rare cancer populations, which account for nearly 25{d450b60efc35a2e17361b5d57bc194208ff1ac62c46bd45a026f4271e6a4dcc4} of all cancer deaths despite minimal commercial research.

#NewToTheStreet #LanternPharma #AIinBiotech #RADRPlatform #CancerResearch #DrugDiscovery #ClinicalTrials #LP184 #RareCancers #Oncology #PrecisionMedicine #BiotechStocks #HealthcareInnovation #StarlightTherapeutics #BrainCancer #Glioblastoma #PediatricCancer #FDAFastTrack #OrphanDrug #AIDrugDiscovery #MedicalBreakthrough #InvestorInsights #NasdaqBiotech